{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T09:29:48Z","timestamp":1787131788813,"version":"build-2736575974"},"reference-count":10,"publisher":"SAGE Publications","issue":"6-7","license":[{"start":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T00:00:00Z","timestamp":1777939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["AIDS Research and Human Retroviruses"],"published-print":{"date-parts":[[2026,7,1]]},"abstract":"<jats:p>\n                    Long-acting injectable cabotegravir\u2013rilpivirine (LA CAB\/RPV) is an antiretroviral option for virologically suppressed people with HIV, but real-world discontinuation and failure patterns remain incompletely described. We retrospectively reviewed 201 adults who received LA CAB\/RPV at a large academic infectious diseases clinic (January 2022\u2013April 2025). Median time on therapy was 380 days (IQR 206\u2013729). At the end of follow-up, 160 (80%) remained on LA CAB\/RPV and 30 (15%) discontinued, most commonly due to insurance barriers (\n                    <jats:italic toggle=\"yes\">n<\/jats:italic>\n                    = 8, 27%); adherence issues and patient preference each accounted for 23% (\n                    <jats:italic toggle=\"yes\">n<\/jats:italic>\n                    = 7). Virologic failure occurred in 4 patients (2%) and was often accompanied by emergent or pre-existing non-nucleoside reverse transcriptase inhibitor and\/or integrase strand transfer inhibitor resistance mutations; all patients achieved resuppression after switching back to oral ART. LA CAB\/RPV was generally well tolerated, but system-level access and care-continuity barriers were major drivers of discontinuation, underscoring the importance of robust support systems and resistance-informed patient selection.\n                  <\/jats:p>","DOI":"10.1177\/08892229261449867","type":"journal-article","created":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T06:38:26Z","timestamp":1778049506000},"page":"227-229","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Real-World Patterns of Discontinuation and Virologic Failure with Long-Acting Cabotegravir\u2013Rilpivirine"],"prefix":"10.1177","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7082-7482","authenticated-orcid":false,"given":"Sara","family":"Hockney","sequence":"first","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, Northwestern University, Chicago, Illinois, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dana","family":"Mueller","sequence":"additional","affiliation":[{"name":"Southwest Infectious Disease and Internal Medicine, Palos Heights, Illinois, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Phillbrick","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, Northwestern University, Chicago, Illinois, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenna","family":"Berlet","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, Northwestern University, Chicago, Illinois, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shannon","family":"Galvin","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, Northwestern University, Chicago, Illinois, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,5,5]]},"reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2508228"},{"key":"e_1_3_2_3_2","unstructured":"ViiV Healthcare. Cabenuva (cabotegravir and rilpivirine) injection for intramuscular use [FDA approval summary]. FDA: Silver Spring MD; 2021. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2021\/212888s000lbl.pdf [Last accessed: Oct13]."},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1097\/qad.0000000000002883"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(20)32666-0"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1904398"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1111\/hiv.70058"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1097\/jnc.0000000000000386"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciae631"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofaf220"},{"key":"e_1_3_2_11_2","article-title":"Real-world utilization and effectiveness of long-acting cabotegravir+ rilpivirine in virologically suppressed treatment experienced individuals in Europe: Data from COMBINE-2 cohort study","author":"Pozniak A","year":"2024","unstructured":"Pozniak A, , Sridhar G, , Assoumou L, et al. Real-world utilization and effectiveness of long-acting cabotegravir+ rilpivirine in virologically suppressed treatment experienced individuals in Europe: Data from COMBINE-2 cohort study. Open Forum Infect Dis, 2024.","journal-title":"Open Forum Infect Dis"}],"container-title":["AIDS Research and Human Retroviruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/08892229261449867","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/08892229261449867","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/08892229261449867","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T09:21:15Z","timestamp":1787131275000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/08892229261449867"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,5]]},"references-count":10,"journal-issue":{"issue":"6-7","published-print":{"date-parts":[[2026,7,1]]}},"alternative-id":["10.1177\/08892229261449867"],"URL":"https:\/\/doi.org\/10.1177\/08892229261449867","relation":{},"ISSN":["0889-2229","1931-8405"],"issn-type":[{"value":"0889-2229","type":"print"},{"value":"1931-8405","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,5]]}}}